GlassScriptPhysician profile
Andres E Mendez-Hernandez
NPI 1487006813
$1,350.32
in general payments reported to CMS, 2019-2025
21 companies · $685 in 2025
The $685 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $122 · 2021: $175 · 2024: $368 · 2025: $685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,053.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,053.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $195.76 | 2020-2021 | |
| Adc Therapeutics America, INC. | $159.96 | 2024-2025 | |
| Kite Pharma, INC. | $151.31 | 2025 | Yescarta |
| Daiichi Sankyo INC. | $123.48 | 2025 | Vanflyta |
| Celgene Corporation | $115.96 | 2024-2025 | Reblozyl, Breyanzi |
| Geron Corporation | $106.12 | 2025 | Rytelo |
| Stemline Therapeutics INC. | $101.25 | 2021 | |
| Legend Biotech USA INC. | $52.46 | 2024-2025 | Carvykti |
| Genentech USA, INC. | $40.17 | 2024-2025 | Venclexta |
| Regeneron Healthcare Solutions, INC. | $37.75 | 2025 | Lynozyfic |
| Genzyme Corporation | $37.72 | 2025 | |
| Janssen Biotech, INC. | $37.20 | 2024-2025 | Tecvayli, Darzalex, Carvykti |
| Astrazeneca Pharmaceuticals LP | $33.69 | 2024-2025 | Calquence |
| Mallinckrodt Hospital Products INC. | $25.41 | 2024 | Cellex |
| Beigene USA, INC. | $22.66 | 2024 | Brukinsa |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $20.86 | 2024 | Tavalisse, Rezlidhia |
| Abbvie INC. | $20.58 | 2024 | |
| Syndax Pharmaceuticals, INC. | $19.95 | 2025 | |
| Pharmaessentia USA Corporation | $19.04 | 2024 | Besremi |
| Alexion Pharmaceuticals, INC. | $14.52 | 2025 | Ultomiris |
| Teleflex LLC | $14.47 | 2025 | Arrow |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andres Mendez-Hernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.